Navigation Links
DRAXIS Health Reports Fourth Quarter and Year End Results
Date:2/7/2008

change pressures caused by a much

stronger Canadian dollar relative to comparable periods in 2006.

Product gross margin for 2007 decreased to 56% compared to 63% for

2006 due to inclusion of freight charges and foreign exchange

pressures.

- Operating income for the fourth quarter of 2007 was $0.8 million and

$4.1 million for all of 2007 compared to $1.6 million and

$5.6 million respectively for the same periods in 2006. The decrease

for both periods in 2007 was due to decreased volumes, pressures on

margins from a strong Canadian dollar, regulatory filing fees and

increased business development activities.

- On October 11, 2007, the Company was informed by Health Canada that

an Abbreviated New Drug Submission ("A/NDS") for DRAXIMAGE(R)

Sestamibi that had been filed by the Company on August 17, 2007 with

Health Canada had been screened and found acceptable for review.

- On December 20, 2007, DRAXIS announced that its radiopharmaceutical

division had appointed GE Healthcare, an industry leader in nuclear

medicine, as the exclusive distributor of DRAXIMAGE(R) Sestamibi in

the United States. DRAXIMAGE has granted GE Healthcare the exclusive

right to market, distribute and sell its generic DRAXIMAGE(R)

Sestamibi in the U.S. market and through its U.S. and Canadian

radiopharmacy network once the primary innovator patent expires and

marketing authorizations are received from the U.S. Food and Drug

Administration (FDA) and Health Canada. Furthermore, GE Healthcare

has agreed to purchase Technetium 99m Sestamibi injection

exclusively from DRAXIMAGE. The initial term of the distribution

agreement is for a minimum of three years following FDA approval of

the DRAXIMAGE product.

-
'/>"/>

SOURCE DRAXIS Health Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
2. DRAXIS to Present at the 2007 UBS Global Life Sciences Conference
3. DRAXIS Health Inc. Announces Retirement of Dr. Martin Barkin as President and Chief Executive Officer
4. DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA
5. DRAXIS Announces Application for Normal Course Issuer Bid
6. DRAXIS Share Buyback Approved by TSX
7. DRAXIS to Report Fourth Quarter and Year End 2007 Results on February 7th
8. Penn study finds pro-death proteins required to regulate healthy immune function
9. UCLA researchers identify markers that may predict diabetes in still-healthy people
10. Air pollution linked to cardiovascular risk indices in healthy young adults
11. More proof needed of safety and quality of electronic personal health records
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... B. E. Smith, the only full-service ... been retained to lead a national chief operating ... in Hermiston, Ore. The top executive search firm ... recently placed more than 900 healthcare executives into organizations. ... progressive, not-for-profit healthcare organization serving a population of more ...
(Date:8/20/2014)... 2014 Biosimilars, which are similar ... through an abbreviated process, could reap billions in ... Information Services, Inc.’s (AIS) Specialty Pharmacy News offers ... the Food and Drug Administration’s (FDA) recent acceptance ... approval. , Drugmaker Sandoz said July 24 that ...
(Date:8/20/2014)... 20, 2014 Building on growing ... successfully predicted stage iii and iv pressure ulcers ... situations, approached 90%. A company spokesperson commented that ... commercial or academic settings. The resulting capabilities can ... of hospital-acquired conditions to help providers avoid financial ...
(Date:8/20/2014)... August 20, 2014 BuyCheapTicketsToEvents.com is ... wide selection of tickets to many events. Cheap NHL hockey ... begin in September. , Hockey fans are enthusiastic about their ... tickets for games. Now is the time to acquire 2014 ... in mere months. There will be a great deal of ...
(Date:8/20/2014)... The “Human Insulin Market by ... Premixed), Modern Human Insulin (Rapid Acting, Long Acting, ... Tresiba, Others) - Forecast to 2019” provides a ... current market trends,and strategies impacting the global human ... of the revenue and share analysis. , Browse ...
Breaking Medicine News(10 mins):Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 3Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 2Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 3Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2Health News:2014 NHL Preseason Tickets Are Among Top Selling Seats at Trusted Provider BuyCheapTicketsToEvents.com 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4
... , , , WOBURN, ... died Wednesday, August 12, 2009 at Massachusetts General Hospital in Boston. Doctors say ... 55 years old. , , Dr. Gilbard is best known ... condition that is caused by a chronic lack of moisture in the eye. ...
... , HATBORO, Pa., Aug. 13 InfoLogix, Inc. (Nasdaq: ... the healthcare and commercial industries, today announced financial results for the quarter ... http://www.newscom.com/cgi-bin/prnh/20090618/NE3513 5 LOGO ) , ... , David T. Gulian, president and chief executive officer ...
... uncertain, researchers say , THURSDAY, Aug. 13 (HealthDay News) ... out and destroy the stem cells that scientists believe ... growing body of research is showing that cancer stem ... causing cancer to reappear even after treatment seems to ...
... , , MECHANICSBURG, Pa., Aug. 13 ... quarter ended June 30, 2009. , , ... revenues increased 3.8% to $559.5 million compared to $538.8 million ... increased 35.0% to $65.4 million compared to $48.4 million for ...
... , , , ... CRDC ) today reported financial results and corporate progress for ... , , "With a slower than expected ... fiscal fourth quarter we had to make difficult decisions to revise ...
... , U.S. Rep. Barbara Lee (D-Calif.) Also to be ... The intensifying debate about health care reform in America will be addressed this ... Aug. 14 at 10 a.m. EDT nationwide on Federal News Radio at ... Washington , D.C. , area. , , ...
Cached Medicine News:Health News:Ophthalmology Pioneer Dr. Jeffrey P. Gilbard Dies 2Health News:Ophthalmology Pioneer Dr. Jeffrey P. Gilbard Dies 3Health News:InfoLogix Announces Second Quarter Financial Results 2Health News:InfoLogix Announces Second Quarter Financial Results 3Health News:InfoLogix Announces Second Quarter Financial Results 4Health News:InfoLogix Announces Second Quarter Financial Results 5Health News:InfoLogix Announces Second Quarter Financial Results 6Health News:InfoLogix Announces Second Quarter Financial Results 7Health News:InfoLogix Announces Second Quarter Financial Results 8Health News:Compound Targets, Destroys Cancer Stem Cells in Mice 2Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 2Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 3Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 4Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 5Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 6Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 7Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 8Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 9Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 10Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 11Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 12Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 13Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 14Health News:Select Medical Corporation Announces Results for Second Quarter Ended June 30, 2009 15Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 2Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 3Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 4Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 5Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 6Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 7Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 8Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 9Health News:Health Care Reform to be Discussed on 'Inside Government' 2
(Date:8/20/2014)... , Aug. 20, 2014  Quantum Materials Corporation ... sets of patent families from Bayer Technology Services GmbH, ... for Bayer AG of Leverkusen, Germany ... provide broad intellectual property protection for advances ... quantum dot (QD) manufacturing. In addition, the Bayer ...
(Date:8/20/2014)... Glenmark Pharmaceuticals S.A. (GPSA), ... India (GPL), announces the discovery and initiation of ... candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR ... Biologics Research Centre located in La Chaux-de-Fonds, ... on Glenmark,s innovative BEAT antibody technology platform which ...
(Date:8/20/2014)... 20, 2014 Phase I Trial ... US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology company ... announces that it has begun a Phase I, First ... KVD001, for the treatment of DME. The study,s Principal ... Eye Institute, Joslin Diabetes Center; Harvard Medical School Department ...
Breaking Medicine Technology:Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Information Systems ("SIS"), a leader in perioperative ... leadership in achieving clinical, financial, and operational goals ... the company,s annual client conference, the 2012 SIS ... systems exemplifying the innovative use of information technology ...
... 2012 Top leaders representing America,s advanced medical ... public policy issues affecting job creation and medical innovation and ... billion medical device tax set to begin in January 2013. ... Renacci (R-Ohio) joined Walter M Rosebrough, president and CEO of ...
Cached Medicine Technology:Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements 2Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements 3Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements 4AdvaMed & BioOhio Discuss MedTech Impact on Ohio's Economy, Job Creation 2AdvaMed & BioOhio Discuss MedTech Impact on Ohio's Economy, Job Creation 3
... reads, writes and prints "Smart" labels. As ... or barcode on the label surface. SATO's ... a range of applications, including: Compliance Labeling, ... Tagging, Retail Labeling, Product Authentication. CL408e RFID ...
... is a core software component ... which enables location-based applications in ... capabilities of the AeroScout Engine ... management of AeroScout hardware and ...
... The Kisses tag is part ... of the Hugs system. The Kisses ... mother after it has been bonded ... her baby. he two tags remain ...
... Radianse active-RFID-tags can be ... For example, that a device ... complete or that a patient ... Every message from an ID-tag ...
Medicine Products: